Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

CVS is set to drop Zepbound as a medicine, but will continue to carry other popular weight loss drugs instead.

Zepbound is an injectable medication approved by the U.S. Food and Drug Administration (FDA) for weight loss, and its key ingredient is tirzepatide. While Zepbound may be a powerful tool for ...

Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults diagnosed with obesity or overweight who have at least one weight-related medical condition.

In the results, dual GLP-1/GIP agonist Zepbound (tirzepatide) outperformed GLP-1 agonist Wegovy (semaglutide) on all weight-loss endpoints at 72 weeks among patients with obesity or who were ...

Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford treatment.